<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="2" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>GB-CHC-1099776-M9-ML</iati-identifier>
  <reporting-org ref="GB-CHC-1099776" type="21" xml:lang="EN">
   <narrative xml:lang="EN">Malaria Consortium</narrative>
  </reporting-org>
  <title xml:lang="EN">
   <narrative xml:lang="EN">ACCESS SMC [Mali]</narrative>
  </title>
  <description type="1" xml:lang="EN">
   <narrative xml:lang="EN">ACCESS SMC will implement Seasonal Malaria Chemoprevention (SMC)  at scale in seven countries in the Sahel, providing approximately 30 percent of total treatments needed for all eligible children per annum in years 2015 and 2016. In the continued fight against malaria in Africa, there is increased recognition of the need to tailor combinations of potential interventions to local needs.  It is in this context that seasonal malaria chemoprevention (SMC) has been approved by the World Health Organization (WHO) and has the potential to become an important tool in the prevention of malaria.  SMC, achieved by administering up to four monthly doses of sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), or SP+AQ, is applicable in areas with high seasonal variation in malaria transmission and where resistance to SP+AQ is low, with the greatest opportunity for impact being in the Sahel.  SMC is targeted at 23.7 million children aged three to 59 months who bear the greatest risk of mortality.  It is highly effective, and has the potential to prevent 75% of uncomplicated and severe malaria cases.  [Mali]</narrative>
  </description>
  <participating-org ref="GB-CHC-1099776" role="4" type="21" xml:lang="EN">
   <narrative xml:lang="EN">Malaria Consortium</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2014-09-01" type="2"></activity-date>
  <activity-date iso-date="2018-02-28" type="3"></activity-date>
  <activity-date iso-date="2018-02-28" type="4"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Malaria Consortium</narrative>
   </organisation>
   <person-name>
    <narrative xml:lang="EN">Malaria Consortium</narrative>
   </person-name>
   <email>iati@malariaconsortium.org</email>
   <mailing-address>
    <narrative xml:lang="EN">The Green House, 244-254 Cambridge Heath Road, London, E2 9DA, United Kingdom</narrative>
   </mailing-address>
  </contact-info>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-tied-status code="5"></default-tied-status>
  <related-activity ref="GB-CHC-1099776-M9" type="1"></related-activity>
 </iati-activity>
</iati-activities>
